Overview

Project concept :Partnership to discover adenosinergic molecules for immuno-oncology therapeutics established between Exscientia and Evotec
Create patentable high quality Strategy assets and value in immuno-oncology

Target class: Specific or bi-specific molecules

Project status: pre-development candidate identified for A2AR inhibitor: Best-in-class
Lead candidate identified for CD73: First-in-class

Primary indication: Combination with immune checkpoint therapies for non responder patients

Administration: Oral administration

Biomarker: Patient stratification: CD73 positive tumour
PD biomarkers and biomarker of activity to detect CD73 inhibition and A2AR inhibition identified

_{1 Evotec, Toulouse, France}

_{2 Exscientia, Oxford, United Kingdom}

_{3 Kinetic Discovery, Oxon, United Kingdom}